MedTrace Logo

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

NCT02843126 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-09-12

No results posted yet for this study

Summary

The aim of this study is the safety and efficacy of Trastuzumab plus natural killer(NK) immunotherapy to recurrent breast cancer.

Conditions

  • Recurrent Breast Cancer

Interventions

DRUG

Trastuzumab

Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)

BIOLOGICAL

NK immunotherapy

For each procedure, 10 billion cells will be infused for 4 times

Sponsors & Collaborators

  • Shenzhen Hank Bioengineering Institute

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Jibing Chen, MD, PhD · Fuda Cancer Hospital, Guangzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2017-07-01
Completion
2019-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02843126 on ClinicalTrials.gov